文献速递消化系统肿瘤

帕尼单抗联合FOLFOX4或FOLFIRI一线治疗伴多发或不可切除肝转移的结直肠癌:一项随机II期试验(PLANET-TTD)

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
PubMed 文献 · Eur J Cancer · 2017-06-19

这项多中心开放标签随机II期研究纳入77例未经治疗、野生型KRAS转移性结直肠癌且伴多发或不可切除肝局限病变的患者,随机接受帕尼单抗联合FOLFOX4或FOLFIRI方案。两组客观缓解率分别为74%和67%,R0-R1切除率分别为34%和46%,中位无进展生存期分别为13个月和14个月,中位总生存期分别为37个月和41个月,疗效无显著差异。帕尼单抗联合FOLFOX4组3/4级中性粒细胞减少和神经病变发生率更高。

要点

  • 帕尼单抗联合FOLFOX4与FOLFIRI一线治疗野生型KRAS转移性结直肠癌伴肝局限病变,客观缓解率分别为74%和67%。
  • 两组R0-R1切除率分别为34%和46%,中位无进展生存期分别为13个月和14个月,中位总生存期分别为37个月和41个月,疗效无显著差异。
  • 帕尼单抗联合FOLFOX4组3/4级中性粒细胞减少(40%对10%,p=0.003)和神经病变(13%对0%,p=0.025)发生率更高。

核心结论

  • 在野生型KRAS转移性结直肠癌伴肝局限病变患者中,一线帕尼单抗联合FOLFOX4或FOLFIRI均获得高客观缓解率和早期肿瘤缩小,使潜在治愈性切除成为可能;两种方案间未观察到疗效的显著差异。

研究设计与样本

  • 多中心、开放标签随机II期研究,纳入年龄≥18岁、未经治疗、野生型KRAS转移性结直肠癌且伴多发或不可切除肝局限病变的患者,随机分配至帕尼单抗联合FOLFOX4组(38例)或帕尼单抗联合FOLFIRI组(39例),共分析77例;其中野生型RAS患者分别为27例和26例。
  • 主要终点为客观缓解率;次要终点包括肝转移灶切除率(R0+R1)、无进展生存期、总生存期、不良事件及围手术期安全性;探索性终点包括按RAS状态分析的缓解、早期肿瘤缩小和缓解深度。

主要发现

  • 客观缓解率在帕尼单抗联合FOLFOX4组为74%,帕尼单抗联合FOLFIRI组为67%;野生型RAS患者中分别为78%和73%。
  • 接受手术切除的患者比例在帕尼单抗联合FOLFOX4组为45%,帕尼单抗联合FOLFIRI组为59%;野生型RAS患者中分别为37%和69%。
  • R0-R1切除率在帕尼单抗联合FOLFOX4组为34%,帕尼单抗联合FOLFIRI组为46%;野生型RAS患者中分别为26%和54%。
  • 中位无进展生存期在帕尼单抗联合FOLFOX4组为13个月,帕尼单抗联合FOLFIRI组为14个月(HR 0.9,95%CI 0.6-1.5);野生型RAS患者中分别为13个月和15个月(HR 0.7,95%CI 0.4-1.3)。
  • 中位总生存期在帕尼单抗联合FOLFOX4组为37个月,帕尼单抗联合FOLFIRI组为41个月(HR 1.0,95%CI 0.6-1.8);野生型RAS患者中分别为39个月和49个月(HR 0.9,95%CI 0.4-1.9)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. However no trial has directly compared these combinations. METHODS: Multicentre, open-label study in untreated patients ≥ 18 years with (WT)-KRAS mCRC and multiple or unresectable liver-limited disease (LLD) randomised to either Pmab-FOLFOX4 or Pmab-FOLFIRI. The primary end-point was objective response rate (ORR). Secondary end-points included liver metastases resection rate (R0 + R1), progression-free survival (PFS), overall survival (OS), adverse events and perioperative safety. Exploratory end-points were: response by RAS status, early tumour shrinkage (ETS) and depth of response (DpR) in WT-RAS patients. RESULTS: Data on 77 patients were analysed (38 Pmab-FOLFOX4; 39 Pmab-FOLFIRI; WT-RAS: 27/26, respectively). ORR was 74% with Pmab-FOLFOX4 and 67% with Pmab-FOLFIRI (WT-RAS: 78%/73%). Out of the above, 45% and 59% underwent surgical resection, respectively (WT-RAS: 37%/69%). The R0-R1 resection rate was 34%/46% (WT-RAS:26%/54%). Median PFS was 13/14 months (hazard ratio [HR] Pmab-FOLFIRI versus Pmab-FOLFOX4: 0.9; 95% confidence interval: [0.6-1.5]; WT-RAS:13/15; HR: 0.7 [0.4-1.3]). Median OS was 37/41 months (HR:1.0 [0.6-1.8]; WT-RAS: 39/49; HR:0.9 [0.4-1.9]). In WT-RAS patients with confirmed response, median DpR was 71%/66%, and 65%/77% of patients showed ETS ≥ 30%/ ≥ 20% at week 8, without significant differences between arms; these patients had longer median PFS and OS and higher resectability rates. Surgery was associated with longer survival. Perioperative and overall safety were similar, except for higher grade 3/4 neutropenia (40%/10%; p = 0.003) and neuropathy (13%/0%; p = 0.025) in the Pmab-FOLFOX4 arm. CONCLUSIONS: In patients with WT-KRAS mCRC and LLD, both first-line Pmab-FOLFOX4 and Pmab-FOLFIRI resulted in high ORR and ETS, allowing potentially curative resection. No significant differences in efficacy were observed between the two regimens. (clinicaltrials.gov:NCT00885885).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Carrato A, Abad A, Massuti B, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017. PMID: 28633089. doi:10.1016/j.ejca.2017.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。